R-phenylpiracetam (MRZ-9547) / Merz Pharma - LARVOL DELTA

The prospect for repurposing of fonturacetam: antihyperactive and antiapathic actions in rats (ECNP 2024) - "In 2014-15 Merz Pharma has patented (r)-fonturacetam (MRZ-9547) as the drug for treatment the motor symptoms of Parkinson's disease and narcolepsy...In our work we aimed to: (1) test whether fonturacetam like the other DAT inhibitors [2,3] reverses a motivation deficit and (2) check if the drug can suppress hyperactivity in DAT-KO rats, the model animals for testing psychostimulators like amphetamine and methylphenidate for antihyperactivity (paradoxical calming) action [4]... Our findings demonstrated that fonturacetam is close to the other clinically used DAT inhibitors and can both mitigate hyperactivity of DAT-KO rats and attenuated tetrabenazine-induced motivation deficit in rats."

Preclinical • CNS Disorders • Narcolepsy • Parkinson's Disease • Sleep Disorder